Trichosporon species), dimorphic fungi and to a lesser extent moulds [3 -8] According to a recent report, crossreaction could also occur in cases of zygomycosis but this warrants further investigations as the results are not supported by previous fi ndings for zygomycetes in the literature [8,9] We described the case of a neutropenic patient presenting with an acute myeloid leukaemia (AML) who was thought to have developed probable IA due to positive results in the GM assay in accord with the EORTC/MSG criteria. However, the etiologic agent was subsequently identifi ed as the rare thermophilic mould Myceliophthora thermophila which was found experimentally to cross react in the Aspergillus galactomannan assay. The patient was successfully treated with voriconazole.
Introduction
Aspergillus galactomannan antigen assay (GM) has been a major advance for managing patients at risk for invasive aspergillosis (IA) especially those with haematological malignancy [1] . Because of its sensitivity and specifi city, GM assay was included several years ago by the EORTC/ MSG as a mycological criterion to defi ne invasive aspergillosis. More recently, a single positive GM, associated with clinical and host criteria, was defi ned as suffi cient for the diagnosis of probable IA [2] . However, in vitro crossreactions (sometimes referred to as false-positivity) with a large number of fungi have been reported in the literature and include yeasts (such as Geotrichum capitatum or initial treatment consisted of two induction regimens (daunorubicin with aracytin followed by mithoxantrone, aracytin and gemtuzumab ozogamicin). Complete haematological remission was achieved and was followed by consolidation therapy with mithoxantrone and aracytin. During aplasia and because the patient presented with fever despite broad-spectrum antibacterial therapy, empiric antifungal therapy with caspofungin was initiated (70 mg/day as a loading dose followed by 50 mg/day). Positive results with the GM (Platelia Aspergillus , Biorad, Marnes la Coquette, France) assay was noted on the 8th consecutive day of aplasia (index 0.97; cut-off value: 0.5) despite the absences of any respiratory symptoms. On the 11th day of aplasia, the patient developed dyspnea, chest pain and moderate hemoptysis. The day after, GM increased to 4.4, and a computed chest tomography scan revealed a large, 35 mm-diameter, subpleural nodule with a halo sign in the upper left pulmonary lobe (Fig. 1) . In light of this probable IA, according to the EORTC/MSG criteria, the patient was given voriconazole (400 mg/day IV) and caspofungin was withdrawn. A bronchoalveolar lavage fl uid (BAL) was sent to the laboratory for microbiological investigations. Serial samples during the hospitalization period were found to be GM positive. Four days later, cultures of the BAL specimen on Sabouraud's dextrose agar medium incubated at 25, 30 and 35°C yielded pure cultures of several colonies of a mould with an unusual aspect. Colonies were fast growing and appeared cinnamon brown, powdery to cottony near the center ( Fig. 2A) . Microscopic examination revealed regular and septate hyphae with ovoid to pyriform conidia borne sessile or arising singly or in small groups from ampulliform stalks (Fig. 2B) . Conidia, were fi nely to coarsely roughened and were hyaline to pale brown pigmented appearing orange brown in mass (Fig. 2C) . Identifi cation of the isolate was achieved through amplifi cation and sequencing of both ITS rDNA and D1/D2 region of the 28S rDNA. Comparison of the nucleotide sequences of the isolate revealed 99.6 % (490 bp) on ITS and 100% similarity on D1/D2 (560 bp) with those of M. thermophila ex-type strain accessioned as UAMH 2474 in the University of Alberta Microfungus Collection and Herbarium, Edmonton, AB. The thermophilic character described for this species was also confi rmed for our isolate (growth at 45, 50, 55 but not at 65 ° C). All bacterial, as well as fungal blood cultures initiated during this patient ' s hospitalization were negative. Antifungal susceptibility testing performed at the French National Reference Center for Mycoses and Antifungals (CNRMA, Institut Pasteur, Paris) according to the EUCAST standardized methodology [10] revealed high MICs against amphotericin B (6 μ g/ml), caspofungin (16 μ g/ml) and itraconazole (1 μ g/ml) but low MICs against voriconazole (0.004 μ g/ml) which was associated with a favourable outcome in our patient. However, a few months later, a relapse of the AML was noted and allogenic stem cell transplantation was scheduled. Prior to transplantation, resection of a segment of a lobe of the lung was performed to prevent invasive disease. To date, no relapse of the fungal infection has been observed.
Discussion
To test if positive GM assay results found with samples from our patient could have been due to cross-reactions with M. thermophila we employed a previously described protocol [3] . Briefl y, fungal conidia of the isolate were suspended in 1 ml sterile distilled water. After vigorous agitation for 1 min, the suspension was centrifuged for 5 min at 10,000 g and the supernatant was collected for GM assay. Then 300 μ l of the supernatant and each of two supplementary dilutions (1:10 and 1:100) were tested in the GM assay according to the manufacturer ' s instructions. Positive ( A. fumigatus ) and negative ( C. albicans ) controls were included in the experiment. All three test samples yielded positive GM results (index at 5.693, 5.237 and 2.370 respectively).
Myceliophthora thermophila is a saprophytic thermophilic mould widely found in the environment especially in self-heating environments such as compost or wood chip piles but it is an infrequent cause of disease in humans [11] . Colonies of this fungus grow rapidly at 35°C, and are fl occulose to powdery with a typical cinnamon color in 4 to 5 days. Microscopic examination revealed septate hyphae along with several obovoidal to pyriform conidia (3.0 -4.5 ϫ 4.5 -11 μ m) arising singly or in small groups from conidiogenous cells. Smooth and pale when young, conidia are fi nely rough and exhibited a typical cinnamon to brown color when mature. Poor outcomes were associated with almost half of the fi ve cases reported since 1992 [12 -16] . Importantly, we confi rmed previous fi ndings of high MICs against amphotericin B and caspofungin, two antifungal drugs used in the management of IA [13] . However, to date, cross-reactivity with GM assay has not been reported. Future studies will have to determine the exact epitope that interacts with the Aspergillus GM assay.
In summary, this report underlines the pathogenic potential of M. thermophila in humans and identifi es a new cause of cross-reaction with the GM assay. These fi ndings highlight that the occurrence of positive Aspergillus GM results must be taken with caution in high-risk patients due to possible cross-reactivity with several emerging or rare fungal species. In this setting, misidentifi cation of these invasive fungal infections could have major clinical consequences if a species exhibiting poor susceptibility to voriconazole is involved. Finally, from an epidemiological perspective, potential GM cross-reactivity must be considered in future studies including patients categorized as having probable IA using the GM as the only mycological criterion.
Nucleotide sequences have been included in Genbank database for the case isolate under accession numbers HQ676489 (ITS) and HQ676490 (D1/D2) and for the reference strain of M. thermophila (ex-type strain UAMH 2474), under numbers HQ724321 (ITS) and HQ724320 (D1/D2). The isolate has been deposited at the University of Alberta Microfungus Collection and Herbarium as UAMH 11479. For personal use only.
